ProQR Therapeutics
PRQR

ProQR Therapeutics (PRQR) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
HC Wainwright & Co.MaintainedBuy$8.00 from $12.00Oct 1, 2026
Chardan CapitalMaintainedBuy$3.00Oct 1, 2026
B of A SecuritiesInitiated CoverageBuy$8.00Aug 20, 2026
Evercore ISI GroupMaintainedOutperform$6.00 from $5.00Jun 29, 2026
Chardan CapitalMaintainedBuy$3.00 from $4.00Jun 26, 2026
Jones TradingMaintainedBuy$10.00 from $11.00Jun 26, 2026
Chardan CapitalMaintainedBuy$4.00Apr 9, 2026
Chardan CapitalMaintainedBuy$4.00Nov 4, 2025
Chardan CapitalMaintainedBuy$4.00Aug 8, 2025
Cantor FitzgeraldMaintainedOverweight$8.00Jun 27, 2025
JMP SecuritiesMaintainedMarket Outperform$8.00Jun 27, 2025
OppenheimerMaintainedOutperform$9.00 from $15.00May 13, 2025
Evercore ISI GroupInitiated CoverageOutperform$5.00Apr 29, 2025
Chardan CapitalMaintainedBuy$4.00Mar 14, 2025
HC Wainwright & Co.MaintainedBuy$12.00 from $10.00Mar 14, 2025
Jones TradingInitiated CoverageBuy$11.00Feb 12, 2025
HC Wainwright & Co.MaintainedBuy$10.00Dec 12, 2024
Chardan CapitalMaintainedBuy$4.00Dec 12, 2024
JMP SecuritiesMaintainedMarket Outperform$8.00Dec 12, 2024
HC Wainwright & Co.MaintainedBuy$10.00 from $5.00Nov 8, 2024

Frequently asked questions

  • What is the latest analyst rating on PRQR?

    On Oct 1, 2026, HC Wainwright & Co. maintained ProQR Therapeutics at Buy with a price target of $8.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.